

Press release from Emotra AB (publ)  
Göteborg, September 19, 2014

## The majority of our clinics have received ethics committee approval

**According to Emotra's planning, the Company had counted on all clinics involved in our study to have received approval by their local ethics committees. Happily, most of the clinics have already received this approval. However, a handful of clinics have not yet received this local approval. The reason for this, in all cases concerned, is that these clinics joined the project at a late stage and have not yet been able to gather all the data required for their ethics committee applications. These delays could lead to the final results of our study being delayed by between one and three months.**

Emotra had previously counted on all clinics being up and running by now, testing patients. However, a handful of clinics have not yet received approval by their local ethics committees. The sole reason for this is difficulties meeting a tight schedule. So far, no ethical objections have been raised about the use of EDOR or the study's approach. The ethics application process does, however, require the presentation of a considerable amount of data and the requirements vary between university ethics committees.

There is a risk that the conclusion of our study may be delayed by a few months, but the Company has been prepared for this, since we cannot decide over the various clinics' allocation of resources. The very reasoning behind our running the Company on a skeleton crew for the time being is to minimize costs and ensure our long-term viability in case of delays.

These ethics committee delays do not necessarily need to have consequences. Any delay in completing the study is dependent, among other things, on how quickly we can include and test a sufficient amount of patients in this multi-centre study.

Emotra will provide an update on the current situation for our clinical study when we have significant news to relay.

*"At present, Emotra is in the middle of a very dynamic phase, and its activities involve an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe,"* says CEO Claes Holmberg.

**For further information, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

**Emotra AB** is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. *Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*